[go: up one dir, main page]

WO2005011649A3 - Methods of treating severe acute respiratory syndrome virus infections - Google Patents

Methods of treating severe acute respiratory syndrome virus infections Download PDF

Info

Publication number
WO2005011649A3
WO2005011649A3 PCT/US2004/015536 US2004015536W WO2005011649A3 WO 2005011649 A3 WO2005011649 A3 WO 2005011649A3 US 2004015536 W US2004015536 W US 2004015536W WO 2005011649 A3 WO2005011649 A3 WO 2005011649A3
Authority
WO
WIPO (PCT)
Prior art keywords
acute respiratory
respiratory syndrome
virus infections
severe acute
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/015536
Other languages
French (fr)
Other versions
WO2005011649A2 (en
Inventor
Mark Denison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of WO2005011649A2 publication Critical patent/WO2005011649A2/en
Publication of WO2005011649A3 publication Critical patent/WO2005011649A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for inhibiting severe acute respiratory syndrome (SARS) virus infections. Specifically, cysteine proteinase inhibitors are proposed as therapeutics for SARS, potentially used in combination with interferons.
PCT/US2004/015536 2003-05-19 2004-05-18 Methods of treating severe acute respiratory syndrome virus infections Ceased WO2005011649A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47160403P 2003-05-19 2003-05-19
US60/471,604 2003-05-19

Publications (2)

Publication Number Publication Date
WO2005011649A2 WO2005011649A2 (en) 2005-02-10
WO2005011649A3 true WO2005011649A3 (en) 2005-03-17

Family

ID=34115298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/015536 Ceased WO2005011649A2 (en) 2003-05-19 2004-05-18 Methods of treating severe acute respiratory syndrome virus infections

Country Status (1)

Country Link
WO (1) WO2005011649A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091610A2 (en) * 2005-02-23 2006-08-31 The Brigham And Women's Hospital, Inc. Inhibitors of enveloped virus infectivity
EP4135685A1 (en) * 2020-04-16 2023-02-22 Albert-Ludwigs-Universität Freiburg Cysteine protease inhibitors for use in the prevention and/or treatment of coronavirus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008769A1 (en) * 1989-12-18 1991-06-27 Transgene S.A. Pharmaceutical composition for treating or preventing retroviral infections
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
WO1999054317A1 (en) * 1998-04-23 1999-10-28 Cortech Inc. Cysteine protease inhibitors
WO2001046448A1 (en) * 1999-12-23 2001-06-28 The Board Of Regents Of The University Of Texas System Inhibition of cellular proteases
WO2004101742A2 (en) * 2003-05-06 2004-11-25 Cytovia, Inc Protease inhibitors for coronaviruses and sars-cov and the use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008769A1 (en) * 1989-12-18 1991-06-27 Transgene S.A. Pharmaceutical composition for treating or preventing retroviral infections
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
WO1999054317A1 (en) * 1998-04-23 1999-10-28 Cortech Inc. Cysteine protease inhibitors
WO2001046448A1 (en) * 1999-12-23 2001-06-28 The Board Of Regents Of The University Of Texas System Inhibition of cellular proteases
WO2004101742A2 (en) * 2003-05-06 2004-11-25 Cytovia, Inc Protease inhibitors for coronaviruses and sars-cov and the use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANAND KANCHAN ET AL: "Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 300, no. 5626, 13 June 2003 (2003-06-13), pages 1763 - 1767, XP002291115, ISSN: 0036-8075 *
KLEINA L G ET AL: "ANTIVIRAL EFFECTS OF A THIOL PROTEASE INHIBITOR ON FOOT-AND-MOUTH DISEASE VIRUS", JOURNAL OF VIROLOGY, NEW YORK, US, US, vol. 66, no. 12, 1 December 1992 (1992-12-01), pages 7168 - 7175, XP000616699, ISSN: 0022-538X *
SELMI C ET AL: "THE SEARCH FOR A PRACTICAL APPROACH TO EMERGING DISEASES: THE CASE OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)", DEVELOPMENTAL IMMUNOLOGY, HARWOOD ACADEMIC PUBLISHERS, NEW YORK, NY,, US, vol. 9, no. 3, September 2002 (2002-09-01), pages 113 - 117, XP009036520, ISSN: 1044-6672 *
SIRCAR S ET AL: "INHIBITION OF ADENOVIRUS INFECTION WITH PROTEASE INHIBITORS", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 30, no. 2/3, May 1996 (1996-05-01), pages 147 - 153, XP001076687, ISSN: 0166-3542 *

Also Published As

Publication number Publication date
WO2005011649A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
EA200600498A1 (en) MACROCYCLIC PEPTIDES THAT EXPRESS ANTI-VIRUS ACTIVITY AGAINST THE HEPATITIS C VIRUS
WO2005042767A3 (en) Compositions and methods for detecting severe acute respiratory syndrome coronavirus
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
WO2008003149A3 (en) Substituted pteridines for the treatment and prevention of viral infections
EP1924593B8 (en) Hcv ns3 protease inhibitors
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2008115281A3 (en) Compounds for treating viral infections
WO2006119061A3 (en) Hcv ns3 protease inhibitors
WO2006104945A3 (en) Hepatitis c therapies
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
UA86599C2 (en) Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
ZA200701629B (en) Gyrase inhibitors and uses thereof
IL171972A0 (en) Compositions and methods for treatment of severe acute respiratory syndrome(sars)
WO2004111147A3 (en) Cyanoacrylate compositions
WO2008073982A3 (en) 5,6-dihydro-1h-pyridin-2-one compounds
EP1649053A4 (en) Characterization of the earliest stages of SEVERE ACUTE RESPIRATORY SYNDROME (SARS) VIRUS, AND APPLICATIONS
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
WO2007132355A3 (en) Compositions and methods for inhibiting viral adhesion
WO2006036817A3 (en) Fungal variants and uses thereof
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase